Loading
Life sciences · Phase 1 Trial
ClinicalTrials.gov · September 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT05891171). This is a study registration, not published results. Lead sponsor: Arcus Biosciences, Inc.. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 40 participants (ACTUAL). Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC). Interventions: DRUG: AB598; DRUG: Zimberelimab; DRUG: Fluorouracil; DRUG: Leucovorin; DRUG: Oxaliplatin. Primary outcome measures: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) , Up to 2 years; Dose Escalation Cohorts: Number of Participants with Dose-Limiting Toxicities (DLTs) , Up to 2 years. Brief summary: The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.